615 related articles for article (PubMed ID: 33165872)
21. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
22. Preclinical characterization of three transient receptor potential vanilloid receptor 1 antagonists for early use in human intradermal microdose analgesic studies.
Sjögren E; Halldin MM; Stålberg O; Sundgren-Andersson AK
Eur J Pain; 2018 May; 22(5):889-903. PubMed ID: 29377430
[TBL] [Abstract][Full Text] [Related]
23. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
Cui M; Gosu V; Basith S; Hong S; Choi S
Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
[TBL] [Abstract][Full Text] [Related]
24. Polypeptide modulators of TRPV1 produce analgesia without hyperthermia.
Andreev YA; Kozlov SA; Korolkova YV; Dyachenko IA; Bondarenko DA; Skobtsov DI; Murashev AN; Kotova PD; Rogachevskaja OA; Kabanova NV; Kolesnikov SS; Grishin EV
Mar Drugs; 2013 Dec; 11(12):5100-15. PubMed ID: 24351908
[TBL] [Abstract][Full Text] [Related]
25. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management.
Pal M; Angaru S; Kodimuthali A; Dhingra N
Curr Pharm Des; 2009; 15(9):1008-26. PubMed ID: 19275664
[TBL] [Abstract][Full Text] [Related]
26. Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies.
Chen R; Coppes OJM; Urman RD
Pain Physician; 2021 Mar; 24(2):153-163. PubMed ID: 33740349
[TBL] [Abstract][Full Text] [Related]
27. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Voight EA; Kort ME
Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
[TBL] [Abstract][Full Text] [Related]
28. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
29. [Capsaicin receptor TRPV1].
Tominaga M
Brain Nerve; 2008 May; 60(5):493-501. PubMed ID: 18516971
[TBL] [Abstract][Full Text] [Related]
30. TRPV1: a therapeutic target for novel analgesic drugs?
Szallasi A; Cruz F; Geppetti P
Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
[TBL] [Abstract][Full Text] [Related]
31. [Involvement of TRPV1 in CNS signaling has opened up the possibility to develop TRPV1 drug therapies].
Zygmunt P
Lakartidningen; 2021 Dec; 118():. PubMed ID: 34894399
[TBL] [Abstract][Full Text] [Related]
32. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
33. TRP channels and pain.
Cortright DN; Szallasi A
Curr Pharm Des; 2009; 15(15):1736-49. PubMed ID: 19442187
[TBL] [Abstract][Full Text] [Related]
34. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
35. TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development.
Garami A; Pakai E; McDonald HA; Reilly RM; Gomtsyan A; Corrigan JJ; Pinter E; Zhu DXD; Lehto SG; Gavva NR; Kym PR; Romanovsky AA
Acta Physiol (Oxf); 2018 Jul; 223(3):e13038. PubMed ID: 29352512
[TBL] [Abstract][Full Text] [Related]
36. Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development.
Hwang SM; Jo YY; Cohen CF; Kim YH; Berta T; Park CK
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628583
[TBL] [Abstract][Full Text] [Related]
37. Mode-selective inhibitory effects of eugenol on the mouse TRPV1 channel.
Takahashi K; Yoshida T; Wakamori M
Biochem Biophys Res Commun; 2021 Jun; 556():156-162. PubMed ID: 33839411
[TBL] [Abstract][Full Text] [Related]
38. Positive allosteric modulation of TRPV1 as a novel analgesic mechanism.
Lebovitz EE; Keller JM; Kominsky H; Kaszas K; Maric D; Iadarola MJ
Mol Pain; 2012 Sep; 8():70. PubMed ID: 22998799
[TBL] [Abstract][Full Text] [Related]
39. Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons.
Chakraborty S; Elvezio V; Kaczocha M; Rebecchi M; Puopolo M
J Physiol; 2017 Apr; 595(8):2639-2660. PubMed ID: 28094445
[TBL] [Abstract][Full Text] [Related]
40. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
Knotkova H; Pappagallo M; Szallasi A
Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
